India's HRV Pharma & Shodhana partner for next-gen APIs

The partnership marks a significant step in advancing high-value, complex APIs aligned with global regulatory standards, including US Drug Master Files (DMFs), while supporting innovation in longevity biology and precision medicine.

Advancing Next-Generation API Development

This collaboration integrates HRV Pharma’s global market access and regulatory execution capabilities with Shodhana Laboratories’ advanced process chemistry and manufacturing infrastructure.

• Development and US DMF filing for pharmaceutical-grade APIs
• Focus on longevity biology and precision medicine applications
• Integration of AI-enabled virtual API development platforms
• End-to-end development from synthesis to commercialization

This approach enables faster development timelines while maintaining strict regulatory and quality standards required for global markets.

Strategic Scope and Capabilities

Under the multi-year agreement, both companies will jointly execute a structured development and commercialization strategy across regulated markets.

• Pipeline of high-science APIs across oncology, CNS, rare diseases, and metabolic disorders
• Global regulatory filings aligned with US FDA, EMA, and other international agencies
• Comprehensive CMC documentation, validation, and stability programs
• Supply chain coordination and commercial execution across multiple regions

The partnership is designed to support pharmaceutical innovators by delivering complex APIs with regulatory clarity and scalable manufacturing readiness.

Leadership Perspective

The collaboration reflects a shared vision to build future-ready pharmaceutical capabilities.

"The API landscape is evolving beyond traditional categories. Filing US DMFs for high-science APIs signals a shift toward the next decade of pharmaceutical innovation. By combining precision chemistry with global regulatory execution, we are building a platform that defines the future of API development," said Hari Kiran Chereddi, Managing Director & CEO, HRV Pharma

Shodhana Laboratories also emphasized the importance of combining scientific precision with global reach to enable high-quality API manufacturing for regulated markets.

Driving Innovation Through Collaboration

The partnership has already initiated multiple development programs, with both organizations working within a milestone-driven framework to accelerate execution.

By leveraging AI-enabled platforms, GMP manufacturing excellence, and global regulatory alignment, HRV Pharma and Shodhana Laboratories aim to unlock new possibilities in complex molecule development.

Looking Ahead

This collaboration reinforces HRV Pharma’s mission to build an asset-light, technology-driven pharmaceutical platform that connects innovation, manufacturing, and global market access.

As demand for precision therapies and complex APIs continues to grow, partnerships like this will play a critical role in shaping the future of pharmaceutical development.

Note: The headline, insights, and image of this press release may have been refined by the ALCHEMPro staff; the rest of the content remains unchanged.

ALCHEMPro News Desk (JP)